Specific targeting of gene expression to a subset of human trabecular meshwork cells using the chitinase 3-like 1 promoter

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 1, 2005, Pages 183-190

  Liton, Paloma B ^a   Liu, Xialin ^a   Stamer, W Daniel ^b   Challa, Pratap ^a   Epstein, David L ^a   Gonzalez, Pedro ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CHITINASE; CHITINASE 3 LIKE 1 PROTEIN; COLLAGEN TYPE 15; FIBULIN; FIBULIN 2; GAMMA SARCOGLYCAN; SARCOGLYCAN; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; GENE THERAPY; GLAUCOMA; HUMAN; HUMAN CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SCHLEMM CANAL; TRABECULAR MESHWORK;

ADENOVIRIDAE; BETA-GALACTOSIDASE; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; COLLAGEN; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; GLYCOPROTEINS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOGLYCANS; TRABECULAR MESHWORK;

EID: 11144320630     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0330     Document Type: Article

References (73)

1. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol. 1989;107:186-188.
2. Quigley HA. Open-angle glaucoma. N Engl J Med. 1993;328:1097-1106.
3. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res. 1971;12:275-281.
4. Tripathi R, Tripathi B. Functional anatomy of the chamber angle. In: Jacobiec F, ed. Ocular Anatomy, Embryology and Teratology. Philadelphia: Harper Row; 1982:197-248.
5. Lütjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res. 1999;18:91-119.
6. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1963;69:783-801.
7. Maepea O, Bill A. Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp Eye Res. 1992;54:879-883.
8. Brubaker RF. The effect of intraocular pressure on conventional outflow resistance in the enucleated human eye. Invest Ophthalmol. 1975;14:286-292.
9. Bill A, Svedbergh B. Scanning electron microscopic studies of the trabecular meshwork and the canal of Schlemm: an attempt to localize the main resistance to outflow of aqueous humor in man. Acta Ophthalmol (Copenh). 1972;50:295-320.
10. Johnson M, Shapiro A, Ethier CR, Kamm RD. Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci. 1992;33:1670-1675.
11. Johnstone MA. Pressure-dependent changes in nuclei and the process origins of the endothelial cells lining Schlemm's canal. Invest Ophthalmol Vis Sci. 1979;18:44-51.
12. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
13. Ethier CR, Kamm RD, Palaszewski BA, Johnson MC, Richardson TM. Calculations of flow resistance in the juxtacanalicular meshwork. Invest Ophthalmol Vis Sci. 1986;27:1741-1750.
14. Gonzalez P, Caballero M, Liton PB, Stamer WD, Epstein DL. Expression analysis of the matrix GLA protein (MGP) and VE-cadherin (VE-cad) gene promoters in the outflow pathway. Invest Ophthalmol Vis Sci. 2004;45:1389-1395.
15. Stamer WD, Roberts BC, Howell DN, Epstein DL. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14:611-617.
16. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation, culture, and characterization of endothelial cells from Schlemm's canal. Invest Ophthalmol Vis Sci. 1998;39:1804-1812.
17. Johnson DH, Tschumper RC. Human trabecular meshwork organ culture: a new method. Invest Ophthalmol Vis Sci. 1987;28:945-953.
18. Gonzalez P, Epstein DL, Borras T. Characterization of gene expression in human trabecular meshwork using single-pass sequencing of 1060 clones. Invest Ophthalmol Vis Sci. 2000;41:3678-3693.
19. Tomarev SI, Wistow G, Raymond V, Dubois S, Malyukova I. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest Ophthalmol Vis Sci. 2003;44:2588-2596.
20. Wirtz MK, Samples JR, Xu H, Severson T, Acott TS. Expression profile and genome location of cDNA clones from an infant human trabecular meshwork cell library. Invest Ophthalmol Vis Sci. 2002;43:3698-3704.
21. Borras T, Matsumoto Y, Epstein DL, Johnson DH. Gene transfer to the human trabecular meshwork by anterior segment perfusion. Invest Ophthalmol Vis Sci. 1998;39:1503-1507.
22. Borras T, Rowlette LL, Erzurum SC, Epstein DL. Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow: relevance for potential gene therapy of glaucoma. Gene Ther. 1999;6:515-524.
23. Budenz DL, Bennett J, Alonso L, Maguire A. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1995;36:2211-2215.
24. Hangai M, Tanihara H, Honda Y, Kaneda Y. Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest Ophthalmol Vis Sci. 1998;39:509-516.
25. Liu X, Brandt CR, Gabelt BT, et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999;69:385-395.
26. Loewen N, Fautsch MP, Peretz M, et al. Genetic modification of human trabecular meshwork with lentiviral vectors. Hum Gene Ther. 2001;12:2109-2119.
27. Loewen N, Bahler C, Teo WL, et al. Preservation of aqueous outflow facility after second-generation FIV vector-mediated expression of marker genes in anterior segments of human eyes. Invest Ophthalmol Vis Sci. 2002;43:3686-3690.
28. Kee C, Sohn S, Hwang JM. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci. 2001;42:2856-2860.
29. Ueda H, Ueda K, Baba T, Ohno S. Delta- and gamma-Sarcoglycan localization in the sarcoplasmic reticulum of skeletal muscle. J Histochem Cytochem. 2001;49:529-538.
30. Barresi R, Moore SA, Stolle CA, Mendell JR, Campbell KP. Expression of gamma-sarcoglycan in smooth muscle and its interaction with the smooth muscle sarcoglycan-sarcospan complex. J Biol Chem. 2000;275:38554-38560.
31. Wakayama Y, Inoue M, Kojima H, et al. Ultrastructural localization of alpha-, beta- and gamma-sarcoglycan and their mutual relation, and their relation to dystrophin, beta-dystroglycan and beta-spectrin in normal skeletal myofiber. Acta Neuropathol (Berl). 1999;97:288-296.
32. Kivirikko S, Saarela J, Myers JC, Autio-Harmainen H, Pihlajaniemi T. Distribution of type XV collagen transcripts in human tissue and their production by muscle cells and fibroblasts. Am J Pathol. 1995;147:1500-1509.
33. Myers JC, Dion AS, Abraham V, Amenta PS. Type XV collagen exhibits a widespread distribution in human tissues but a distinct localization in basement membrane zones. Cell Tissue Res. 1996;286:493-505.
34. Hagg PM, Hagg PO, Peltonen S, Autio-Harmainen H, Pihlajaniemi T. Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol. 1997;150:2075-2086.
35. Cho H, Kim WJ, Lee YM, et al. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Oncol Rep. 2004;11:191-195.
36. John H, Preissner KT, Forssmann WG, Standker L. Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. Biochemistry. 1999;38:10217-10224.
37. Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun. 1999;255:735-739.
38. Sasaki T, Hohenester E, Timpl R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life. 2002;53:77-84.
39. Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol. 2000;301:1179-1190.
40. Tsuda T, Wang H, Timpl R, Chu ML. Fibulin-2 expression marks transformed mesenchymal cells in developing cardiac valves, aortic arch vessels, and coronary vessels. Dev Dyn. 2001;222:89-100.
41. Pan TC, Sasaki T, Zhang RZ, et al. Structure and expression of fibulin-2, a novel extracellular matrix protein with multiple EGF-like repeats and consensus motifs for calcium binding. J Cell Biol. 1993;123:1269-1277.
42. Gu YC, Talts JF, Gullberg D, Timpl R, Ekblom M. Glucocorticoids down-regulate the extracellular matrix proteins fibronectin, fibulin-1 and fibulin-2 in bone marrow stroma. Eur J Haematol. 2001;67:176-184.
43. Hamanaka T, Bill A, Ichinohasama R, Ishida T. Aspects of the development of Schlemm's canal. Exp Eye Res. 1992;55:479-488.
44. Ethier CR. The inner wall of Schlemm's canal. Exp Eye Res. 2002;74:161-172.
45. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221-225.
46. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803-25810.
47. Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110:351-360.
48. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford). 1999;38:618-626.
49. Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int. 2001;20:192-196.
50. Johansen JS, Kirwan JR, Price PA, Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol. 2001;30:297-304.
51. Bernardi D, Podswiadek M, Zaninotto M, Punzi L, Plebani M. YKL-40 as a marker of joint involvement in inflammatory bowel disease. Clin Chem. 2003;49:1685-1688.
52. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003;38:599-605.
53. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis. 2003;18:254-259.
54. Johansen JS, Moller S, Price PA, et al. Plasma YKL-40: a new potential marker of flbrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol. 1997;32:582-590.
55. Johansen JS, Christoffersen P, Moller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 2000;32:911-920.
56. Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer. 1995;31:1437-1442.
57. Cintin C, Johansen JS, Christensen IJ, et al. Serum YKL-40 and colorectal cancer. Br J Cancer. 1999;79:1494-1499.
58. Dehn H, Hogdall EV, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstetr Gynecol Scand. 2003;82:287-293.
59. Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat. 2003;80:15-21.
60. Shostak K, Labunskyy V, Dmitrenko V, et al. HC gp-39 gene is upregulated in glioblastomas. Cancer Lett. 2003;198:203-210.
61. Boot RG, van Achterberg TA, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999;19:687-694.
62. Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624-2630.
63. Register TC, Carlson CS, Adams MR. Serum YKL-40 is associated with osteoarthritis and atherosclerosis in nonhuman primates. Clin Chem. 2001;47:2159-2161.
64. De Ceuninck F, Gaufillier S, Bonnaud A, et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285:926-931.
65. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365:119-126.
66. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003;287:79-87.
67. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63:8614-8622.
68. Gonzalez P, Zigler JS, Jr., Epstein DL, Borras T. Identification and isolation of differentially expressed genes from very small tissue samples. Biotechniques. 1999;26:884-886, 888-892.
69. Rehli M, Niller HH, Ammon C, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278:44058-44067.
70. Volck B, Ostergaard K, Johansen JS, Garbarsch C, Price PA. The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Scand J Rheumatol. 1999;28:171-179.
71. Lo WR, Rowlette LL, Caballero M, et al. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci. 2003;44:473-485.
72. Miyahara T, Kikuchi T, Akimoto M, et al. Gene microarray analysis of experimental glaucomatous retina from cynomolgus monkey. Invest Ophthalmol Vis Sci. 2003;44:4347-4356.
73. Dozin B, Malpeli M, Camardella L, Cancedda R, Pietrangelo A. Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: molecular and cellular aspects. Matrix Biol. 2002;21:449-459.